CASPIAN: Phase III Study of First-line Durvalumab + Tremelimumab + EP vs Durvalumab + EP vs EP Alone in Extensive-Stage SCLC

May 29-31, 2020; Online at meetings.asco.org/am
Updated analysis finds durvalumab + EP maintains significant OS improvement vs EP alone with no further benefit with addition of tremelimumab.
Format: Microsoft PowerPoint (.ppt)
File Size: 455 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

A brief slideset covering key concepts and data on antibody-drug conjugates for advanced NSCLC from Clinical Care Options (CCO)

D. Ross Camidge, MD, PhD Joel W. Neal, MD, PhD Released: March 4, 2021

In this slideset from Clinical Care Options, a panel of international experts review the role of immunotherapy for patients with endometrial cancer.

person default Mansoor Raza Mirza, MD Bradley J. Monk, MD, FACS, FACOG Prof Isabelle Ray Coquard Released: March 2, 2021

Expert faculty reviews key clinical trials in relapsed extensive-stage small-cell lung cancer from the 2020 World Conference on Lung Cancer, from Clinical Care Options (CCO)

Nicolas Girard, MD, PhD Released: March 1, 2021

Domenica Lorusso, MD, PhD, on the molecular reclassification of endometrial cancers and key ongoing immunotherapy trials, from Clinical Care Options (CCO)

Domenica Lorusso, MD, PhD Released: February 25, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue